结合组织生物标志物与多参数磁共振诊断临床显著性前列腺癌:PICTURE研究中21种生物标志物的分析
基于PICTURE研究组织微阵列(5 mm间隔活检)与多参数磁共振(mpMRI)数据,分析21种前列腺癌生物标志物。AGR2、CD10和EGR蛋白在配对恶性与良性组织中表达显著不同;AMACR、ANPEP、GDF15、MSMB、PSMA、PTEN、TBL1XR1、TP63、VPS13A和VPS28在恶性组织不同Gleason分级间表达显著不同。多数标志物与mpMRI数据不相关,仅AMACR和PTEN在病理与影像评估中均被识别。
要点
- AGR2、CD10和EGR蛋白在配对前列腺恶性与良性组织中表达显著不同。
- AMACR、ANPEP、GDF15、MSMB、PSMA、PTEN、TBL1XR1、TP63、VPS13A和VPS28在恶性组织不同Gleason分级间表达显著不同。
- 多数受检标志物与mpMRI数据不相关,AMACR和PTEN在病理与影像评估中均被识别。
核心结论
- 亟需开发有助于前列腺癌诊断和预后的生物标志物,组织生物标志物因免疫组化廉价、可靠且病理科广泛可用而特别受关注。
- 在当前诊断路径一致的队列中检测生物标志物,对识别具有潜在临床实用价值的标志物至关重要。
研究设计与样本
- 使用来自PICTURE研究的组织微阵列(活检间隔5 mm)及mpMRI数据,分析21种前列腺癌生物标志物。
- 生物标志物基于现有文献选择,分析其区分良恶性组织的能力,并与病理分级、mpMRI、血清PSA、年龄和家族史进行相关性分析。
主要发现
- AGR2、CD10和EGR蛋白在配对的恶性和良性组织中表达显著不同。
- AMACR、ANPEP、GDF15、MSMB、PSMA、PTEN、TBL1XR1、TP63、VPS13A和VPS28在恶性组织不同Gleason分级间表达显著不同。
- 多数受检生物标志物与mpMRI数据不相关。
- CD10、KHDRBS3、PCLAF、PSMA、SIK2和GDF15随前列腺癌进展而差异表达。
- AMACR和PTEN在病理和影像数据评估中均被识别。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serum PSA and digital rectal examination remain the key diagnostic tools for detecting prostate cancer. However, due to the limited specificity of serum PSA, the applicability of this marker continues to be controversial. Recent use of image-guided biopsy along with pathological assessment and the use of biomarkers has dramatically improved the diagnosis of clinically significant cancer. Despite the two modalities working together for diagnosis biomarker research often fails to correlate findings with imaging. METHODS AND RESULTS: We looked at 21 prostate cancer biomarkers correlating our results with mpMRI data to investigate the hypothesis that biomarkers along with mpMRI data make a powerful tool to detect clinically significant prostate cancer. Biomarkers were selected based on the existing literature. Using a tissue microarray comprised of samples from the PICTURE study, with biopsies at 5 mm intervals and mpMRI data we analysed which biomarkers could differentiate benign and malignant tissue. Biomarker data were also correlated with pathological grading, mpMRI, serum PSA, age and family history. AGR2, CD10 and EGR protein expression was significantly different in both matched malignant and benign tissues. AMACR, ANPEP, GDF15, MSMB, PSMA, PTEN, TBL1XR1, TP63, VPS13A and VPS28 showed significantly different expression between Gleason grades in malignant tissue. The majority of the biomarkers tested did not correlate with mpMRI data. However, CD10, KHDRBS3, PCLAF, PSMA, SIK2 and GDF15 were differentially expressed with prostate cancer progression. AMACR and PTEN were identified in both pathological and image data evaluation. CONCLUSIONS: There is a high demand to develop biomarkers that would help the diagnosis and prognosis of prostate cancer. Tissue biomarkers are of particular interest since immunohistochemistry remains a cheap, reliable method that is widely available in pathology departments. These results demonstrate that testing biomarkers in a cohort consistent with the current diagnostic pathway is crucial to identifying biomarker with potential clinical utility.
引用
- Stopka-Farooqui U, Stavrinides V, Simpson BS, et al. Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study. Prostate Cancer Prostatic Dis. 2024. PMID: 39578642. doi:10.1038/s41391-024-00920-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。